TNF and Behcet disease: Over the past decade, the off-label use of TNF-α antagonists such as infliximab, adalimumab, etanercept and golimumab has improved the treatment of refractory immune-mediated uveitis, especially in BD, and there is sufficient evidence to suggest that TNF-α inhibition is an important development in the treatment of patients with severe and resistant BD (101–103).